[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341677-105":59,"doc-detail-341677-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","non-small-cell-lung-cancer-sensitisation-to-platinum-chemotherapy-via-new-thiazole-triazole-hybrids-acting-as-dual-t-type-ccbmmp-9-inhibitors","Non-small cell lung cancer sensitisation to platinum chemotherapy via new thiazole-triazole hybrids - Acting as dual T-type CCB/MMP-9 inhibitors","","Cisplatin is the standard therapy for non-small cell lung cancer, yet drug resistance and oxidative-stress toxicity limit curative outcomes. Resistance is associated with matrix metalloproteinase overexpression and dysregulated calcium signalling. The study synthesizes new thiazole-triazole hybrids designed as MMP-9 inhibitors with T-type calcium channel blocking and antioxidant effects to enhance cisplatin sensitivity and reduce toxicity. Cell viability, whole-cell patch clamp, selectivity, and docking/MD simulations support a lead candidate (6d) with nanomolar MMP-9 inhibition and synergism with cisplatin.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/non-small-cell-lung-cancer-sensitisation-to-platinum-chemotherapy-via-new-thiazole-triazole-hybrids-acting-as-dual-t-type-ccbmmp-9-inhibitors/341677/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/non-small-cell-lung-cancer-sensitisation-to-platinum-chemotherapy-via-new-thiazole-triazole-hybrids-acting-as-dual-t-type-ccbmmp-9-inhibitors/341677.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is cisplatin not fully curative for non-small cell lung cancer?","Question",{"text":113,"@type":114},"Cisplatin is limited by drug resistance and oxidative-stress-induced toxicity. Resistance is linked to MMP overexpression and aberrant calcium signalling, which together reduce treatment effectiveness.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is the purpose of the new thiazole-triazole hybrids in this study?",{"text":118,"@type":114},"The hybrids are synthesized to act as MMP-9 inhibitors while also providing T-type calcium channel blocking and antioxidant effects. This combination aims to sensitize non-small cell lung cancer to cisplatin and ameliorate its toxicity.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the combination studies show with the lead hybrid 6d and cisplatin?",{"text":122,"@type":114},"The combination studies confirmed synergy between 6d and cisplatin. Cisplatin’s IC50 was lowered by 6.89-fold under the combined regimen.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341677,1790211021,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","ReseaRch aRticle  \nNon-small cell lung cancer sensitisation to platinum chemotherapy via newthiazole-triazole hybrids acting as dual T-type CCB/MMP-9 inhibitors  \nhassan Gamala, Khadiga a. ismaila,b, a-Mohsen M. e. Omara, Mohamed teleba, Marwa M. abu-seriec, sun huangd, abdalla s. abdelsattare, Gerald W. Zamponid and hesham Fahmyf  \nadepartment of Pharmaceutical chemistry, faculty of Pharmacy, alexandria university, alexandria, Egypt; bfaculty of Pharmacy, alamein International university (aIu), alamein city, Egypt; cdepartment of medical biotechnology, Genetic Engineering and biotechnology research Institute, city of scientific research and technological applications (srta-city), Egypt; ddepartment of clinical neurosciences, hotchkiss brain Institute, university of calgary, calgary, canada; ecenter for microbiology and Phage therapy, zewail city of sciences and technology, october Gardens, Giza, Egypt; fdepartment of Pharmaceutical sciences, college of Pharmacy and allied health Professions, south dakota state university, brookings, sd, usa  \nABSTRACT  \ncisplatin remains the unchallenged standard therapy for Nsclc. however, it is not completely curative due to drug resistance and oxidative stress-induced toxicity. Drug resistance is linked to overexpression of matrix metalloproteinases (MMPs) and aberrant calcium signalling. We report synthesis of novel thiazole-triazole hybrids as MMP-9 inhibitors with t-type calcium channel blocking and antioxidant effects to sensitise Nsclc to cisplatin and ameliorate its toxicity. Mtt and whole cell patch clamp assays revealed that 6d has a balanced profile of cytotoxicity (ic50 = 21 ± 1 nM, si = 12.14) and t-type calcium channel blocking activity (⁓60% at 10 μM). it exhibited moderate ROs scavenging activity and nanomolar MMP-9 inhibition (ic50 = 90 ± 7 nM) surpassing NNGh with MMP-9 over −2 and MMP-10 over −13 selectivity. Docking and MDs simulated its receptor binding mode. combination studies confirmed that 6d synergized with cisplatin (ci = 0.69 ± 0.05) lowering its ic50 by 6.89 folds. Overall, the study introduces potential lead adjuvants for Nsclc platinum-based therapy.  \nGRAPHICAL ABSTRACT  \nARTICLE HISTORY  \nreceived 9 may 2024 revised 16 July 2024 accepted 30 July 2024  \nKEYWORDS  \nmmP-9; t-type calcium channel; cisplatin; adjuvant therapy; lung cancer  \nCONTACT hesham fahmy  [hesham.fahmy@sdstate.edu](hesham.fahmy@sdstate.edu)  department of Pharmaceutical sciences, college of Pharmacy and allied health Professions, south dakota state university, brookings, south dakota, usa  \n supplemental data for this article can be accessed online at [https://doi.org/10.1080/14756366.2024.2388209](https://doi.org/10.1080/14756366.2024.2388209) .  \n© 2024 the author(s) . Published by Informa uK limited, trading as taylor & francis Group  \nthis is an open access article distributed under the terms of the creative commons attribution-noncommercial license ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. the terms on which this article has been published allow the posting of the accepted manuscript in a repository by the author(s) or with their consent.  \n2  h. GaMal et al.  \nIntroduction  \nlung cancer is the second most prevalent type of cancer, with approximately two million new cases and over two million deaths worldwide in [2020. it](2020. it) has a high fatality rate, leading to the highest rate of mortality among men with cancer in 93 countries1. Non-small cell lung cancer (Nsclc), related to tobacco-driven tumorigenesis, accounts for most [cases](cases2 . surgery)[2](cases2 . surgery)[ . surgery](cases2 . surgery) is the primary treatment for early-stage lung cancer3. however, the majority of patients suffer advanced incurable Nsclc stages, when they are first diagnosed4, or they relapse after surger","cbCaijJYay9sZpex","https://ap.wps.com/l/cbCaijJYay9sZpex","pdf",3591273,22,"English","# Abstract\n## Introduction\n## Materials and Methods (implied by assays)\n## Results (assay findings and lead optimization)\n## Discussion (mechanisms and therapeutic implications)","[{\"question\":\"Why is cisplatin not fully curative for non-small cell lung cancer?\",\"answer\":\"Cisplatin is limited by drug resistance and oxidative-stress-induced toxicity. Resistance is linked to MMP overexpression and aberrant calcium signalling, which together reduce treatment effectiveness.\"},{\"question\":\"What is the purpose of the new thiazole-triazole hybrids in this study?\",\"answer\":\"The hybrids are synthesized to act as MMP-9 inhibitors while also providing T-type calcium channel blocking and antioxidant effects. This combination aims to sensitize non-small cell lung cancer to cisplatin and ameliorate its toxicity.\"},{\"question\":\"What did the combination studies show with the lead hybrid 6d and cisplatin?\",\"answer\":\"The combination studies confirmed synergy between 6d and cisplatin. Cisplatin’s IC50 was lowered by 6.89-fold under the combined regimen.\"}]","Non-small cell lung cancer sensitisation to platinum chemotherapy via new thiazole-triazole hybrids - Acting as dual T-type CCB/MMP-9 inhibitors | PDF",1790043149,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b999ed4f98e1cf203f65d58aac34950.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16ed5d8d1e69d01f0010d04bef42aefb.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d003e5f7e024a2755d176516a670f4d7.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef02668c86f6e0c7cf4f6e7929cc82db.webp",980,1268]